secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-117228
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia Q3 net loss $7.3M; acquired US rights to APP13007; appointed new director
--------------------------------------------------------------------------------

- Net loss of ~$7.3M ($0.18 EPS) in Q3 2023, vs ~$7.3M loss ($0.21 EPS) in Q3 2022.
- Cash & equivalents $20.7M at Sept 30, 2023, down from $22.9M at Dec 31, 2022.
- Acquired US commercial rights to APP13007 (post-surgical ocular pain/inflammation); PDUFA date March 4, 2024.
- FDA approved Coastline International as Mydcombi contract manufacturer; national launch planned early 2024.
- Michael Geltzeiler appointed as independent director and Audit Committee chair, effective Nov 14, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465923117228/0001104659-23-117228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465923117228/tm2330550d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer